Table of Contents

1.       Research Methodology

2.       Project Scope & Definitions

3.       Impact of Covid-19 on Japan Influenza Vaccine Market

4.       Executive Summary

5.       Japan Influenza Vaccine Market Outlook, FY2017-FY2031

5.1.    Market Size & Forecast

5.1.1.By Value

5.1.2.By Volume

5.1.      By Type of Vaccine

5.1.1.       Inactivated Influenza Vaccine

5.1.2.       Live Attenuated Influenza Vaccine

5.2.    By Type of Influenza

5.2.1.Seasonal

5.2.2.Pandemic

5.3.    By Formulation

5.3.1.       Trivalent

5.3.1.1.  Standard Dose Unadjuvanted

5.3.1.2.  High Dose Unadjuvanted

5.3.1.3.  Adjuvanted

5.3.2.       Quadrivalent

5.3.2.1.  Standard Dose Unadjuvanted

5.3.2.2.  Unadjuvanted

5.4.    By Technology

5.4.1.       Egg-based

5.4.2.       Cell culture

5.4.3.       Recombinant

5.5.      By Age Group

5.5.1.       Paediatric

5.5.2.       Adult

5.6.      By Route of Administration

5.6.1.       Intra-muscular injection

5.6.2.       Nasal Spray

5.7.      By Distribution Channel

5.7.1.       Hospital

5.7.2.       Retail Pharmacies

5.7.3.       Government Suppliers

5.7.4.       Others

5.8.      By Region

5.8.1.       North [Hokkaido and Tohoku]

5.8.2.       Central [Kanto and Chubu]

5.8.3.       South [Kansai, Chugoku, Shikoku, and Kyushu & Okinawa]

5.9.      By Company Market Share (%), FY2023

6.            Market Mapping, FY2023

7.1. By Category

7.2. By Type of Influenza

7.3. By Formulation

7.4. By Technology

7.5. By Age Group

7.6. By Route of Administration

7.7. By Distribution Channel

7.8. By Region

8.       Macro Environment and Industry Structure

8.1. Demand Supply Analysis

8.2. Import Export Analysis

8.3. Value Chain Analysis

8.4. PESTEL Analysis

8.4.1.       Political Factors

8.4.2.       Economic System

8.4.3.       Social Implications

8.4.4.       Technological Advancements

8.4.5.       Environmental Impacts

8.4.6.       Legal Compliances and Regulatory Policies (Statutory Bodies Included)

8.5. Porter’s Five Forces Analysis

8.5.1.       Supplier Power

8.5.2.       Buyer Power

8.5.3.       Substitution Threat

8.5.4.       Threat from New Entrant

8.5.5.       Competitive Rivalry

9.       Market Dynamics

9.1.    Growth Drivers

9.2.    Growth Inhibitors (Challenges and Restraints)

10.   Regulatory Framework and Innovation

10.1.          Clinical Trials

10.2.          Patent Landscape

10.3.          Regulatory Approvals

10.4.          Innovations/Emerging Technologies

11.   Key Players Landscape

11.1.          Competition Matrix of Top Five Market Leaders

11.2.          Market Revenue Analysis of Top Five Market Leaders (in %, FY2023)

11.3.          Mergers and Acquisitions/Joint Ventures (If Applicable)

11.4.          SWOT Analysis (For Five Market Players)

11.5.          Patent Analysis (If Applicable)

12.   Pricing Analysis

13.   Case Studies

14.   Key Players Outlook

14.1.                Daiichi Sankyo Co., Ltd,

14.1.1.    Company Details

14.1.2.    Key Management Personnel

14.1.3.    Products & Services

14.1.4.    Financials (As reported)

14.1.5.    Key Market Focus & Geographical Presence

14.1.6.    Recent Developments

14.2.          BIKEN Co., Ltd.

14.3.          Denka Seiken Co., Ltd.

14.4.          KM biologics Co., Ltd.

14.5.          Takeda Pharmaceutical Company Limited.

14.6.          Chugai Pharmaceutical Co., Ltd.

14.7.          Shionogi & Co., Ltd.

14.8.          Astellas Pharma Inc.

14.9.          Mitsubishi Tanabe Pharma Corporation.

14.10.      FUJIFILM Toyama Chemical Co., Ltd.

14.11.      GC Biopharma Corp.

*Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work

15.   Strategic Recommendations

16.   About Us & Disclaimer